A comprehensive investigation reveals an extensive network trafficking counterfeit and substandard pharmaceuticals across India, exposing critical vulnerabilities in drug supply chain management. The illicit operation has resulted in severe health consequences for patients relying on compromised medications. This exposé highlights inadequate regulatory oversight, insufficient tracking mechanisms, and systemic weaknesses that enable fraudsters to infiltrate legitimate distribution channels, threatening public health infrastructure and demanding urgent reform.

Summary auto-generated by AI from the original publisher's content. Editorial standards.